ARTICLE | Finance
Proteome roam
Why Arch, Versant backed Vividion’s proteome-wide drug discovery platform
February 4, 2017 12:44 AM UTC
Arch Venture Partners and Versant Ventures co-led Vividion Therapeutics Inc.’s $50 million series A round because they think the company’s platform could improve drug discovery across the board by dramatically expanding accessible targets in the human proteome and expediting their translation.
Participation in last week’s round included existing investor Cardinal Partners, which seeded Vividion in 2014 to spin out technology developed at The Scripps Research Institute...